<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRANDIN- repaglinide tablet </strong><br>Carilion Materials Management<br></p></div>
<h1><span class="Bold">PRANDIN (repaglinide) Tablets (0.5, 1, and 2 mg)
            <span class="Sup">® </span></span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_06607c57-dbf2-4006-b282-b521930aa5fd"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">PRANDIN (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (also known as non-insulin dependent <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus or <span class="product-label-link" type="condition" conceptid="201826" conceptname="Type 2 diabetes mellitus">NIDDM</span>). Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)-butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues.
                            <span class="Sup">®</span></p>
<p>The structural formula is as shown below:</p>
<div class="Figure">
<a name="id538"></a><img alt="Fig. 1 - Structural Formula of Prandin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2a07020-a596-4282-bb7c-c9ebe6edcd61&amp;name=95b23ad0-0278-445b-81c7-487b386089f4-01.jpg">
</div>
<p>Repaglinide is a white to off-white powder with molecular formula C H N O and a molecular weight of 452.6. PRANDIN tablets contain 0.5 mg, 1 mg, or 2 mg of repaglinide. In addition each tablet contains the following inactive ingredients: calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, maize starch, polacrilin potassium, povidone, glycerol (85%), magnesium stearate, meglumine, and poloxamer. The 1 mg and 2 mg tablets contain iron oxides (yellow and red, respectively) as coloring agents.
                            <span class="Sub">27</span><span class="Sub">36</span><span class="Sub">2</span><span class="Sub">4</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_73549ade-41d9-46b4-9cc0-c3f96e4d5e1f"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_26d0b55b-ba33-4285-aa28-b874d60d1195"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations.</p>
<p>Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_75410a0f-bc14-47e7-8472-5425696b5bea"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">After oral administration, repaglinide is rapidly and completely absorbed from the gastrointestinal tract. After single and multiple oral doses in healthy subjects or in patients, peak plasma drug levels (C ) occur within 1 hour (T ). Repaglinide is rapidly eliminated from the blood stream with a half-life of approximately 1 hour. The mean absolute bioavailability is 56%. When repaglinide was given with food, the mean T was not changed, but the mean C and AUC (area under the time/plasma concentration curve) were decreased 20% and 12.4%, respectively.
                                    <span class="Bold">Absorption:</span><span class="Sub">max</span><span class="Sub">max</span><span class="Sub">max</span><span class="Sub">max</span></p>
<p>After intravenous (IV) dosing in healthy subjects, the volume of distribution at steady state (V ) was 31 L, and the total body clearance (CL) was 38 L/h. Protein binding and binding to human serum albumin was greater than 98%.
                                    <span class="Bold">Distribution:</span><span class="Sub">ss</span></p>
<p>Repaglinide is completely metabolized by oxidative biotransformation and direct conjugation with glucuronic acid after either an IV or oral dose. The major metabolites are an oxidized dicarboxylic acid (M2), the aromatic amine (M1), and the acyl glucuronide (M7). The cytochrome P-450 enzyme system, specifically 2C8 and 3A4, have been shown to be involved in the N-dealkylation of repaglinide to M2 and the further oxidation to M1. Metabolites do not contribute to the glucose-lowering effect of repaglinide.
                                    <span class="Bold">Metabolism:</span></p>
<p>Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1).</p>
<p>Within 96 hours after dosing with C-repaglinide as a single, oral dose, approximately 90% of the radiolabel was recovered in the feces and approximately 8% in the urine. Only 0.1% of the dose is cleared in the urine as parent compound. The major metabolite (M2) accounted for 60% of the administered dose. Less than 2% of parent drug was recovered in feces.
                                    <span class="Bold">Excretion:</span><span class="Sup">14</span></p>
<p>The pharmacokinetic parameters of repaglinide obtained from a single-dose, crossover study in healthy subjects and from a multiple-dose, parallel, dose-proportionality (0.5, 1, 2 and 4 mg) study in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> are summarized in the following table:
                                    <span class="Bold">Pharmacokinetic Parameters:</span></p>
<table>
<col width="31%">
<col width="69%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>dosed preprandially with three meals</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Toprule" valign="top"><p class="First"><span class="Bold">Patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Dose</p>
<p>0.5 mg</p>
<p>1 mg</p>
<p>2 mg</p>
<p>4 mg</p>
</td>
<td class="Botrule" valign="top">
<p class="First">AUC Mean ±SD (ng/mL*hr):
                                                    <span class="Sub">0-24 hr</span></p>
<p>68.9 ± 154.4</p>
<p>125.8 ± 129.8</p>
<p>152.4 ± 89.6</p>
<p>447.4 ± 211.3</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Dose</p>
<p>0.5 mg</p>
<p>1 mg</p>
<p>2 mg</p>
<p>4 mg</p>
</td>
<td class="Botrule" valign="top">
<p class="First">C Mean ±SD (ng/mL):
                                                    <span class="Sub">max0-5 hr</span></p>
<p>9.8 ± 10.2</p>
<p>18.3 ± 9.1</p>
<p>26.0 ± 13.0</p>
<p>65.8 ± 30.1</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Dose</p>
<p>0.5 - 4 mg</p>
</td>
<td class="Botrule" valign="top">
<p class="First">T Means (SD)
                                                    <span class="Sub">max0-5 hr</span></p>
<p>1.0 - 1.4 (0.3 - 0.5) hr</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Dose</p>
<p>0.5 - 4 mg</p>
</td>
<td class="Botrule" valign="top">
<p class="First">T Means (Ind Range)
                                                    <span class="Sub">½</span></p>
<p>1.0 - 1.4 (0.4 - 8.0) hr</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Parameter</p></td>
<td class="Botrule" valign="top"><p class="First">Healthy Subjects</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">CL based on i.v.</p></td>
<td class="Botrule" valign="top"><p class="First">38 ± 16 L/hr</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">V based on i.v.
                                                    <span class="Sub">ss</span></p></td>
<td class="Botrule" valign="top"><p class="First">31 ± 12 L</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">AbsBio</p></td>
<td class="Botrule" valign="top"><p class="First">56 ± 9%</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule" valign="top"></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" colspan="2" valign="top">
<p class="First">CL= total body clearance</p>
<p>V = volume of distribution at steady state
                                                    <span class="Sub">ss</span></p>
<p>AbsBio = absolute bioavailability</p>
</td></tr>
</tbody>
</table>
<p>These data indicate that repaglinide did not accumulate in serum. Clearance of oral repaglinide did not change over the 0.5 - 4 mg dose range, indicating a linear relationship between dose and plasma drug levels.</p>
<p>Repaglinide AUC after multiple doses of 0.25 to 4 mg with each meal varies over a wide range. The intra-individual and inter-individual coefficients of variation were 36% and 69%, respectively. AUC over the therapeutic dose range included 69 to 1005 ng/mL*hr, but AUC exposure up to 5417 ng/mL*hr was reached in dose escalation studies without apparent adverse consequences.
                                    <span class="Bold">Variability of Exposure:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4d24080c-6e41-490f-826e-5e2820194658"></a><a name="section-2.3"></a><p></p>
<h2>Special Populations</h2>
<p class="First">Healthy volunteers were treated with a regimen of 2 mg taken before each of 3 meals. There were no significant differences in repaglinide pharmacokinetics between the group of patients &lt;65 years of age and a comparably sized group of patients ≥65 years of age (See ).
                                    <span class="Bold">Geriatric:</span><span class="Bold">PRECAUTIONS,</span><a href="#i4i_geriatric_use_id_4bf26ba7-bfd5-4ce5-8a06-fa66e74a01b0">Geriatric Use</a></p>
<p>No studies have been performed in pediatric patients.
                                    <span class="Bold">Pediatric:</span></p>
<p>A comparison of pharmacokinetics in males and females showed the AUC over the 0.5 mg to 4 mg dose range to be 15% to 70% higher in females with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. This difference was not reflected in the frequency of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic episodes</span> (male: 16%; female: 17%) or other adverse events. With respect to gender, no change in general dosage recommendation is indicated since dosage for each patient should be individualized to achieve optimal clinical response.
                                    <span class="Bold">Gender:</span></p>
<p>No pharmacokinetic studies to assess the effects of race have been performed, but in a U.S. 1-year study in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, the blood glucose-lowering effect was comparable between Caucasians (n=297) and African-Americans (n=33). In a U.S. dose-response study, there was no apparent difference in exposure (AUC) between Caucasians (n=74) and Hispanics (n=33).
                                    <span class="Bold">Race:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef642c99-a140-43c3-a1c3-21d637967d9e"></a><a name="section-2.4"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First">Drug interaction studies performed in healthy volunteers show that PRANDIN had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline, or warfarin. Co-administration of cimetidine with PRANDIN did not significantly alter the absorption and disposition of repaglinide.</p>
<p>Additionally, the following drugs were studied in healthy volunteers with co-administration of PRANDIN. Listed below are the results:</p>
<p><span class="Bold"><span class="Italics">CYP2C8 and CYP3A4 Inhibitors/Inducer</span></span></p>
<p>: Co-administration of gemfibrozil (600 mg) and a single dose of 0.25 mg PRANDIN (after 3 days of twice-daily 600 mg gemfibrozil) resulted in an 8.1-fold higher repaglinide AUC and prolonged repaglinide half-life from 1.3 to 3.7 hr.  Co-administration with itraconazole and a single dose of 0.25 mg PRANDIN (on the third day of a regimen of 200 mg initial dose, twice-daily 100 mg itraconazole) resulted in a 1.4-fold higher repaglinide AUC. Co-administration of both gemfibrozil and itraconazole with PRANDIN resulted in a 19-fold higher repaglinide AUC and prolonged repaglinide half-life to 6.1 hr.   Plasma repaglinide concentration at 7 h increased 28.6-fold with gemfibrozil co-administration and 70.4-fold with the gemfibrozil-itraconazole combination (see , ).
                                    <span class="Italics">Gemfibrozil and Itraconazole</span><span class="Bold"><a href="#i4i_contraindications_id_c23f38b8-81f4-4e60-8f54-bde23807f011">CONTRAINDICATIONS</a></span><span class="Bold">PRECAUTIONS,
                                        <a href="#i4i_interactions_id_489ca531-d24d-4687-a3a8-b0db04b83e1f">Drug-Drug Interactions</a></span></p>
<p>Co-administration of 200 mg fenofibrate with a single dose of 0.25 mg repaglinide (after 5 days of once daily fenofibrate 200 mg) resulted in unchanged AUC and C values for both drugs.
                                    <span class="Italics">Fenofibrate:</span><span class="Sub">max</span></p>
<p>: Co-administration of 200 mg ketoconazole and a single dose of 2 mg PRANDIN (after 4 days of once daily ketoconazole 200 mg) resulted in a 15% and 16% increase in repaglinide AUC and C , respectively. The increases were from 20.2 ng/mL to 23.5 ng/mL for C and from 38.9 ng/mL*hr to 44.9 ng/mL*hr for AUC.
                                    <span class="Italics">Ketoconazole</span><span class="Sub">max</span><span class="Sub">max</span></p>
<p>Co-administration of 160 mg trimethoprim and a single dose of 0.25 mg PRANDIN (after 2 days of twice daily and one dose on the third day of trimethoprim 160 mg) resulted in a 61% and 41% increase in repaglinide AUC and C , respectively. The increase in AUC was from 5.9 ng/mL*hr to 9.6 ng/mL*hr and the increase in C was from 4.7 ng/mL to 6.6 ng/mL.
                                    <span class="Italics">Trimethoprim:</span><span class="Sub">max</span><span class="Sub">max</span></p>
<p>: Co-administration of 100 mg cyclosporine with a single dose of 0.25 mg repaglinide (after two 100 mg doses of cyclosporine twelve hours apart) increased the repaglinide (0.25 mg) C 1.8-fold and the AUC 2.5-fold in an interaction study with healthy volunteers (see , ).
                                    <span class="Bold"><span class="Italics">Cyclosporine</span></span><span class="Sub">max</span><span class="Bold">PRECAUTIONS</span><a href="#i4i_interactions_id_489ca531-d24d-4687-a3a8-b0db04b83e1f">Drug-Drug Interactions</a></p>
<p>: Co-administration of 600 mg rifampin and a single dose of 4 mg PRANDIN (after 6 days of once daily rifampin 600 mg) resulted in a 32% and 26% decrease in repaglinide AUC and C , respectively. The decreases were from 40.4 ng/mL to 29.7 ng/mL for C and from 56.8 ng/mL*hr to 38.7 ng/mL*hr for AUC.
                                    <span class="Bold"><span class="Italics">Rifampin</span></span><span class="Sub">max</span><span class="Sub">max</span></p>
<p>In another study, co-administration of 600 mg rifampin and a single dose of 4 mg PRANDIN (after 6 days of once daily rifampin 600 mg) resulted in a 48% and 17% decrease in repaglinide median AUC and median C respectively. The median decreases were from 54 ng/mL*hr to 28 ng/mL*hr for AUC and from 35 ng/mL to 29 ng/mL for C . PRANDIN administered by itself (after 7 days of once daily rifampin 600 mg) resulted in an 80% and 79% decrease in repaglinide median AUC and C respectively. The decreases were from 54 ng/mL*hr to 11 ng/mL*hr for AUC and from 35 ng/mL to 7.5 ng/mL for C .
                                    <span class="Sub">max</span><span class="Sub">max</span><span class="Sub">max</span><span class="Sub">max</span></p>
<p>Co-administration of a combination tablet of 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol administered once daily for 21 days with 2 mg PRANDIN administered three times daily (days 1-4) and a single dose on Day 5 resulted in 20% increases in repaglinide, levonorgestrel, and ethinyl estradiol C The increase in repaglinide C was from 40.5 ng/mL to 47.4 ng/mL. Ethinyl estradiol AUC parameters were increased by 20%, while repaglinide and levonorgestrel AUC values remained unchanged.
                                    <span class="Bold"><span class="Italics">Levonorgestrel &amp; Ethinyl Estradiol:</span></span><span class="Sub">max.</span><span class="Sub">max</span></p>
<p>Co-administration of 20 mg simvastatin and a single dose of 2 mg PRANDIN (after 4 days of once daily simvastatin 20 mg and three times daily PRANDIN 2 mg) resulted in a 26% increase in repaglinide C from 23.6 ng/mL to 29.7 ng/mL. AUC was unchanged.
                                    <span class="Bold"><span class="Italics">Simvastatin:</span></span><span class="Sub">max</span></p>
<p>Co-administration of 10 mg nifedipine with a single dose of 2 mg PRANDIN (after 4 days of three times daily nifedipine 10 mg and three times daily PRANDIN 2 mg) resulted in unchanged AUC and C values for both drugs.
                                    <span class="Bold"><span class="Italics">Nifedipine:</span></span><span class="Sub">max</span></p>
<p>Co-administration of 250 mg clarithromycin and a single dose of 0.25 mg PRANDIN (after 4 days of twice daily clarithromycin 250 mg) resulted in a 40% and 67% increase in repaglinide AUC and C , respectively. The increase in AUC was from 5.3 ng/mL*hr to 7.5 ng/mL*hr and the increase in C was from 4.4 ng/mL to 7.3 ng/mL.
                                    <span class="Bold"><span class="Italics">Clarithromycin:</span></span><span class="Sub">max</span><span class="Sub">max</span></p>
<p>Co-administration of deferasirox (30 mg/kg/day for 4 days) and repaglinide (single dose of 0.5 mg) resulted in an increase in repaglinide systemic exposure (AUC) to 2.3-fold of control and an increase in C of 62% (see ).
                                    <span class="Bold"><span class="Italics">Deferasirox:</span></span><span class="Sub">max</span><span class="Bold">PRECAUTIONS,
                                        <a href="#i4i_interactions_id_489ca531-d24d-4687-a3a8-b0db04b83e1f">Drug-Drug Interactions</a></span></p>
<p>Single-dose and steady-state pharmacokinetics of repaglinide were compared between patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and normal renal function (CrCl &gt; 80 mL/min), mild to moderate renal function impairment (CrCl = 40 – 80 mL/min), and severe renal function impairment (CrCl = 20 – 40 mL/min). Both AUC and C of repaglinide were similar in patients with normal and mild to moderately <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (mean values 56.7 ng/mL*hr vs 57.2 ng/mL*hr and 37.5 ng/mL vs 37.7 ng/mL, respectively.) Patients with severely reduced renal function had elevated mean AUC and C values (98.0 ng/mL*hr and 50.7 ng/mL, respectively), but this study showed only a weak correlation between repaglinide levels and creatinine clearance. Initial dose adjustment does not appear to be necessary for patients with mild to moderate renal dysfunction.
                                    <span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span>:</span><span class="Sub">max</span><span class="Sub">max</span><span class="Bold">However, patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who have renal function impairment should initiate PRANDIN therapy with the 0.5 mg dose – subsequently, patients should be carefully titrated. Studies were not conducted in patients with creatinine clearances below 20 mL/min or patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> requiring hemodialysis.
                                        <span class="Italics">severe</span></span></p>
<p>A single-dose, open-label study was conducted in 12 healthy subjects and 12 patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> (CLD) classified by Child-Pugh scale and caffeine clearance. Patients with moderate to severe impairment of liver function had higher and more prolonged serum concentrations of both total and unbound repaglinide than healthy subjects (AUC : 91.6 ng/mL*hr; AUC : 368.9 ng/mL*hr; C : 46.7 ng/mL; C : 105.4 ng/mL). AUC was statistically correlated with caffeine clearance. No difference in glucose profiles was observed across patient groups. Patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> may be exposed to higher concentrations of repaglinide and its associated metabolites than would patients with normal liver function receiving usual doses. Therefore,
                                    <span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>:</span><span class="Sub">healthy</span><span class="Sub">CLD patients</span><span class="Sub">max, healthy</span><span class="Sub">max, CLD patients</span><span class="Bold">PRANDIN should be used cautiously in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. Longer intervals between dose adjustments should be utilized to allow full assessment of response.</span></p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_f1b29e3f-ad55-45cb-9487-ef5b3ec06c90"></a><a name="section-2.5"></a><p></p>
<h2>Clinical Trials</h2>
<p class="First"><span class="Bold">Monotherapy Trials</span></p>
<p>A four-week, double-blind, placebo-controlled dose-response trial was conducted in 138 patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> using doses ranging from 0.25 to 4 mg taken with each of three meals. PRANDIN therapy resulted in dose-proportional glucose lowering over the full dose range. Plasma insulin levels increased after meals and reverted toward baseline before the next meal. Most of the fasting blood glucose-lowering effect was demonstrated within 1-2 weeks.</p>
<p>In a double-blind, placebo-controlled, 3-month dose titration study, PRANDIN or placebo doses for each patient were increased weekly from 0.25 mg through 0.5, 1, and 2 mg, to a maximum of 4 mg, until a fasting plasma glucose (FPG) level &lt;160 mg/dL was achieved or the maximum dose reached. The dose that achieved the targeted control or the maximum dose was continued to end of study. FPG and 2-hour post-prandial glucose (PPG) increased in patients receiving placebo and decreased in patients treated with repaglinide. Differences between the repaglinide- and placebo-treated groups were -61 mg/dL (FPG) and -104 mg/dL (PPG). The between-group change in HbA , which reflects long-term glycemic control, was 1.7% units.
                                    <span class="Sub">1c</span></p>
<a name="_Refid_4b7259a6-ffa2-4931-865c-113fa4e9d"></a><table>
<caption><span>PRANDIN vs. Placebo Treatment: Mean FPG, PPG, and HbA Changes from baseline after 3 months of treatment:
                                        <span class="Sub">1c</span></span></caption>
<col width="20%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>p &lt; 0.05 for between group difference</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">PPG (mg/dL)</span></p></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">HbA (%)
                                                        <span class="Sub">1c</span></span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">PL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">R</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">PL</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">R</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">PL</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">R</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Baseline</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">215.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">220.2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">245.2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">261.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8.1</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">8.5</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top">
<p class="First">Change from Baseline</p>
<p>(at last visit)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">30.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-31.0
                                                    <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">56.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-47.6
                                                    <a href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">-0.6
                                                    <a href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" colspan="7" valign="top">
<p class="First">FPG = fasting plasma glucose</p>
<p>PPG = post-prandial glucose</p>
<p>PL = placebo (N=33)</p>
<p>R = repaglinide (N=66)</p>
</td></tr>
</tbody>
</table>
<p>Another double-blind, placebo-controlled trial was carried out in 362 patients treated for 24 weeks. The efficacy of 1 and 4 mg preprandial doses was demonstrated by lowering of fasting blood glucose and by HbA at the end of the study. HbA for the PRANDIN- treated groups (1 and 4 mg groups combined) at the end of the study was decreased compared to the placebo-treated group in previously naïve patients and in patients previously treated with oral hypoglycemic agents by 2.1% units and 1.7% units, respectively. In this fixed-dose trial, patients who were naïve to oral hypoglycemic agent therapy and patients in relatively good glycemic control at baseline (HbA below 8%) showed greater blood glucose-lowering including a higher frequency of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Patients who were previously treated and who had baseline HbA ≥ 8% reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> at the same rate as patients randomized to placebo. There was no average gain in body weight when patients previously treated with oral hypoglycemic agents were switched to PRANDIN. The average <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in patients treated with PRANDIN and not previously treated with sulfonylurea drugs was 3.3%.
                                    <span class="Sub">1c</span><span class="Sub">1c</span><span class="Sub">1c</span><span class="Sub">1c</span></p>
<p>The dosing of PRANDIN relative to meal-related insulin release was studied in three trials including 58 patients. Glycemic control was maintained during a period in which the meal and dosing pattern was varied (2, 3 or 4 meals per day; before meals x 2, 3, or 4) compared with a period of 3 regular meals and 3 doses per day (before meals x 3). It was also shown that PRANDIN can be administered at the start of a meal, 15 minutes before, or 30 minutes before the meal with the same blood glucose-lowering effect.</p>
<p>PRANDIN was compared to other insulin secretagogues in 1-year controlled trials to demonstrate comparability of efficacy and safety. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was reported in 16% of 1228 PRANDIN patients, 20% of 417 glyburide patients, and 19% of 81 glipizide patients. Of PRANDIN-treated patients with symptomatic <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, none developed <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or required hospitalization.</p>
<p><span class="Bold">Combination Trials</span></p>
<p>PRANDIN was studied in combination with metformin in 83 patients not satisfactorily controlled on exercise, diet, and metformin alone. PRANDIN dosage was titrated for 4 to 8 weeks, followed by a 3-month maintenance period. Combination therapy with PRANDIN and metformin resulted in significantly greater improvement in glycemic control as compared to repaglinide or metformin monotherapy. HbA was improved by 1% unit and FPG decreased by an additional 35 mg/dL. In this study where metformin dosage was kept constant, the combination therapy of PRANDIN and metformin showed dose-sparing effects with respect to PRANDIN. The greater efficacy response of the combination group was achieved at a lower daily repaglinide dosage than in the PRANDIN monotherapy group (see Table).
                                    <span class="Sub">1c</span></p>
<a name="_Refid_c37ff352-e677-49e3-9654-1e01eb378"></a><table>
<caption><span>PRANDIN and Metformin Therapy: Mean Changes from Baseline in Glycemic Parameters and Weight after 4 to 5 Months of Treatment
                                        <a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span></caption>
<col width="27%">
<col width="20%">
<col width="35%">
<col width="19%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>based on intent-to-treat analysis</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>p &lt; 0.05, for pairwise comparisons with PRANDIN and metformin.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>p &lt; 0.05, for pairwise comparison with metformin.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"> </p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PRANDIN</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Combination</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">28</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">27</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">27</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First"><span class="Bold">Median Final Dose</span></p>
<p><span class="Bold">(mg/day)</span></p>
</td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">6 (PRANDIN)</p>
<p>1500 (metformin)</p>
</td>
<td class="Botrule" align="center" valign="top"><p class="First">1500</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">HbA (% units)
                                                        <span class="Sub">1c</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-0.38</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-1.41
                                                    <a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">-0.33</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8.8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-39.2
                                                    <a href="#footnote-4" class="Sup">†</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">-4.5</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Weight (kg)</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3.0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.4
                                                    <a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">-0.90</p></td>
</tr>
</tbody>
</table>
<p>A combination therapy regimen of PRANDIN and pioglitazone was compared to monotherapy with either agent alone in a 24-week trial that enrolled 246 patients previously treated with sulfonylurea or metformin monotherapy (HbA &gt; 7.0%). Numbers of patients treated were: PRANDIN (N = 61), pioglitazone (N = 62), combination (N = 123). PRANDIN dosage was titrated during the first 12 weeks, followed by a 12-week maintenance period. Combination therapy resulted in significantly greater improvement in glycemic control as compared to monotherapy (figure below). The changes from baseline for completers in FPG (mg/dL) and HbA (%), respectively were: -39.8 and -0.1 for PRANDIN, -35.3 and -0.1 for pioglitazone and -92.4 and -1.9 for the combination. In this study where pioglitazone dosage was kept constant, the combination therapy group showed dose-sparing effects with respect to PRANDIN (see figure legend). The greater efficacy response of the combination group was achieved at a lower daily repaglinide dosage than in the PRANDIN monotherapy group. Mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increases</span> associated with combination, PRANDIN and pioglitazone therapy were 5.5 kg, 0.3 kg, and 2.0 kg respectively.
                                    <span class="Sub">1c</span><span class="Sub">1c</span></p>
<p><span class="Bold">HbA Values from PRANDIN / Pioglitazone Combination Study
                                        <span class="Sub">1c</span></span></p>
<div class="Figure">
<a name="id897"></a><img alt="Fig. 2 - Prandin Pioglitazone Combination Study" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2a07020-a596-4282-bb7c-c9ebe6edcd61&amp;name=95b23ad0-0278-445b-81c7-487b386089f4-02.jpg">
</div>
<p>HbA values by study week for patients who completed study (combination, N = 101; PRANDIN, N = 35, pioglitazone, N = 26).
                                    <span class="Sub">1c</span></p>
<p>Subjects with FPG above 270 mg/dL were withdrawn from the study.</p>
<p>Pioglitazone dose: fixed at 30 mg/day; PRANDIN median final dose: 6 mg/day for combination and 10 mg/day for monotherapy.</p>
<p>A combination therapy regimen of PRANDIN and rosiglitazone was compared to monotherapy with either agent alone in a 24-week trial that enrolled 252 patients previously treated with sulfonylurea or metformin (HbA &gt; 7.0%). Combination therapy resulted in significantly greater improvement in glycemic control as compared to monotherapy (table below). The glycemic effects of the combination therapy were dose-sparing with respect to both total daily PRANDIN dosage and total daily rosiglitazone dosage (see table legend). A greater efficacy response of the combination therapy group was achieved with half the median daily dose of PRANDIN and rosiglitazone, as compared to the respective monotherapy groups. Mean weight change associated with combination therapy was greater than that of PRANDIN monotherapy.
                                    <span class="Sub">1c</span></p>
<a name="_Refid_53939cd2-7140-4872-b48d-5f26e5e85"></a><table>
<caption><span>Mean Changes from Baseline in Glycemic Parameters and Weight in a 24-Week PRANDIN/Rosiglitazone Combination Study
                                        <a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></caption>
<col width="27%">
<col width="22%">
<col width="26%">
<col width="26%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>based on intent-to-treat analysis</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>p-value ≤ 0.001 for comparison to either monotherapy</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>p-value &lt; 0.001 for comparison to PRANDIN</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PRANDIN</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Combination</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Rosiglitazone</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">N</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">63</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">127</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">62</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">HbA (%)
                                                        <span class="Sub">1c</span></span></p></td>
<td class="Botrule" colspan="3" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Baseline</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9.1</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">9.0</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Change by 24 weeks</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-0.17</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-1.43
                                                    <a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">-0.56</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">FPG (mg/dL)</span></p></td>
<td class="Botrule" colspan="3" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Baseline</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">269</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">257</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">252</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Change by 24 weeks</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-54</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">-94
                                                    <a href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">-67</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Change in Weight (kg)</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+1.3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">+4.5
                                                    <a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">+3.3</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule" colspan="4" valign="top"><p class="First">Final median doses: rosiglitazone - 4 mg/day for combination and 8 mg/day for monotherapy; PRANDIN - 6 mg/day for combination and 12 mg/day for monotherapy</p></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_521e7a39-9d06-4793-8b16-2fab2ffb0571"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PRANDIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_c23f38b8-81f4-4e60-8f54-bde23807f011"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PRANDIN is contraindicated in patients with:</p>
<dl>
<dt>1.</dt>
<dd><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span>, with or without <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. This condition should be treated with insulin.
                                </dd>
<dt>2.</dt>
<dd>Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
                                </dd>
<dt>3.</dt>
<dd>Co-administration of gemfibrozil.
                                </dd>
<dt>4.</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug or its inactive ingredients.
                                </dd>
</dl>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_1330a63a-eda5-4e62-9001-c347cb18f5fa"></a><a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_50a8a02d-3c40-489c-af14-6d4b4a702ce7"></a><a name="section-5.1"></a><p></p>
<h2>General:</h2>
<p class="First">PRANDIN is not indicated for use in combination with NPH-insulin (See ).
                                    <span class="Bold">ADVERSE REACTIONS,
                                        <a href="#i4i_section_id_c43fbd02-7818-4796-9839-2d7f03683446">Cardiovascular Events</a></span></p>
<p><span class="Bold">Macrovascular Outcomes:</span></p>
<p>There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with PRANDIN or any other anti-diabetic drug.</p>
<p>All oral blood glucose-lowering drugs including repaglinide are capable of producing <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Proper patient selection, dosage, and instructions to the patients are important to avoid <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic episodes</span>. <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic insufficiency</span> may cause elevated repaglinide blood levels and may diminish gluconeogenic capacity, both of which increase the risk of serious <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. Elderly, debilitated, or malnourished patients, and those with adrenal, pituitary, hepatic, or severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> may be particularly susceptible to the hypoglycemic action of glucose-lowering drugs.
                                    <span class="Bold"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>:</span></p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> may be difficult to recognize in the elderly and in people taking beta-adrenergic blocking drugs. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.</p>
<p>The frequency of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> is greater in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> who have not been previously treated with oral blood glucose-lowering drugs (naïve) or whose HbA is less than 8%. PRANDIN should be administered with meals to lessen the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
                                    <span class="Sub">1c</span></p>
<p>When a patient stabilized on any diabetic regimen is exposed to stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, a loss of glycemic control may occur. At such times, it may be necessary to discontinue PRANDIN and administer insulin. The effectiveness of any hypoglycemic drug in lowering blood glucose to a desired level decreases in many patients over a period of time, which may be due to progression of the severity of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or to diminished responsiveness to the drug. This phenomenon is known as secondary failure, to distinguish it from primary failure in which the drug is ineffective in an individual patient when the drug is first given. Adequate adjustment of dose and adherence to diet should be assessed before classifying a patient as a secondary failure.
                                    <span class="Bold">Loss of Control of Blood Glucose:</span></p>
<p><span class="Bold">Information for Patients</span></p>
<p>Patients should be informed of the potential risks and advantages of PRANDIN and of alternative modes of therapy. They should also be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of blood glucose and HbA . The risks of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, its symptoms and treatment, and conditions that predispose to its development and concomitant administration of other glucose-lowering drugs should be explained to patients and responsible family members. Primary and secondary failure should also be explained.
                                    <span class="Sub">1c</span></p>
<p>Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal.
                                    <span class="Bold">Patients should be instructed to take PRANDIN before meals (2, 3, or 4 times a day preprandially).</span><span class="Bold">Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.</span></p>
<p><span class="Bold">Laboratory Tests</span></p>
<p>Response to all diabetic therapies should be monitored by periodic measurements of fasting blood glucose and <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> levels with a goal of decreasing these levels towards the normal range. During dose adjustment, fasting glucose can be used to determine the therapeutic response. Thereafter, both glucose and <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> should be monitored. <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">Glycosylated hemoglobin</span> may be especially useful for evaluating long-term glycemic control. Postprandial glucose level testing may be clinically helpful in patients whose pre-meal blood glucose levels are satisfactory but whose overall glycemic control (HbA ) is inadequate.
                                    <span class="Sub">1c</span></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_489ca531-d24d-4687-a3a8-b0db04b83e1f"></a><a name="section-5.2"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First">data indicate that PRANDIN is metabolized by cytochrome P450 enzymes 2C8 and 3A4.  Consequently, repaglinide metabolism may be altered by drugs which influence these cytochrome P450 enzyme systems via induction and inhibition.  Caution should therefore be used in patients who are on PRANDIN and taking inhibitors and/or inducers of CYP2C8 and CYP3A4. The effect may be very significant if both enzymes are inhibited at the same time resulting in a substantial increase in repaglinide plasma concentrations. Drugs that are known to inhibit CYP3A4 include antifungal agents like ketoconazole, itraconazole, and antibacterial agents like erythromycin. Drugs that are known to inhibit CYP2C8 include agents like trimethoprim, gemfibrozil and montelukast. Drugs that induce the CYP3A4 and/or 2C8 enzyme systems include rifampin, barbiturates, and carbamezapine. See section, .
                                    <span class="Italics">In vitro</span><span class="Bold">CLINICAL PHARMACOLOGY</span><span class="Bold"><a href="#i4i_section_id_ef642c99-a140-43c3-a1c3-21d637967d9e">Drug-Drug Interactions</a></span></p>
<p>Repaglinide appears to be a substrate for active hepatic uptake transporter (organic anion transporting protein OATP1B1). Drugs that inhibit OATP1B1 (e.g. cyclosporine) may likewise have the potential to increase plasma concentrations of repaglinide. See section, .
                                    <span class="Bold">CLINICAL PHARMACOLOGY</span><span class="Bold"><a href="#i4i_section_id_ef642c99-a140-43c3-a1c3-21d637967d9e">Drug-Drug Interactions</a></span></p>
<p>data from a study that evaluated the co-administration of a cytochrome P450 enzyme 3A4 inhibitor, clarithromycin, with PRANDIN resulted in a clinically significant increase in repaglinide plasma levels. In addition, an increase in repaglinide plasma levels was observed in studies that evaluated the co-administration of PRANDIN with trimethoprim and PRANDIN with deferasirox, both cytochrome P-450 enzyme 2C8 inhibitors. These increases in repaglinide plasma levels may necessitate a PRANDIN dose adjustment. See section, .
                                    <span class="Italics">In vivo</span><span class="Bold">CLINICAL PHARMACOLOGY</span><span class="Bold"><a href="#i4i_section_id_ef642c99-a140-43c3-a1c3-21d637967d9e">Drug-Drug Interactions</a></span></p>
<p>Gemfibrozil significantly increased PRANDIN exposure. Therefore, patients should not take PRANDIN with gemfibrozil. See section, , and .
                                    <span class="Bold">CLINICAL PHARMACOLOGY</span><span class="Bold"><a href="#i4i_section_id_ef642c99-a140-43c3-a1c3-21d637967d9e">Drug-Drug Interactions</a></span><span class="Bold"><a href="#i4i_contraindications_id_c23f38b8-81f4-4e60-8f54-bde23807f011">CONTRAINDICATIONS</a></span></p>
<p>The hypoglycemic action of oral blood glucose-lowering agents may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, cyclosporine, chloramphenicol, coumarins, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. When such drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for loss of glycemic control.</p>
<p>Certain drugs tend to produce <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may lead to loss of glycemic control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When these drugs are administered to a patient receiving oral blood glucose-lowering agents, the patient should be observed for loss of glycemic control. When these drugs are withdrawn from a patient receiving oral blood glucose-lowering agents, the patient should be observed closely for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_20a7d002-aba2-4955-b6f7-f56bda445eb4"></a><a name="section-5.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment Of Fertility</h2>
<p class="First">Long-term carcinogenicity studies were performed for 104 weeks at doses up to and including 120 mg/kg body weight/day (rats) and 500 mg/kg body weight/day (mice) or approximately 60 and 125 times clinical exposure, respectively, on a mg/m basis. No evidence of carcinogenicity was found in mice or female rats. In male rats, there was an increased incidence of benign <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> of the thyroid and liver. The relevance of these findings to humans is unclear. The no-effect doses for these observations in male rats were 30 mg/kg body weight/day for <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span> and 60 mg/kg body weight/day for <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>, which are over 15 and 30 times, respectively, clinical exposure on a mg/m basis.
                                    <span class="Sup">2</span><span class="Sup">2</span></p>
<p>Repaglinide was non-genotoxic in a battery of and studies: Bacterial mutagenesis (Ames test), forward cell mutation assay in V79 cells (HGPRT), chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, unscheduled and replicating DNA synthesis in rat liver, and mouse and rat micronucleus tests.
                                    <span class="Italics">in vivo</span><span class="Italics">in vitro</span><span class="Italics">in vitro</span><span class="Italics">in vitro</span><span class="Italics">in vivo</span></p>
<p>Fertility of male and female rats was unaffected by repaglinide administration at doses up to 80 mg/kg body weight/day (females) and 300 mg/kg body weight/day (males); over 40 times clinical exposure on a mg/m basis.
                                    <span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8adfb7d4-d110-4744-986d-46798af052d9"></a><a name="section-5.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Pregnancy category C</p>
<p>: Safety in pregnant women has not been established. Repaglinide was not teratogenic in rats or rabbits at doses 40 times (rats) and approximately 0.8 times (rabbit) clinical exposure (on a mg/m basis) throughout pregnancy. Because animal reproduction studies are not always predictive of human response, PRANDIN should be used during pregnancy only if it is clearly needed.
                                    <span class="Bold">Teratogenic Effects</span><span class="Sup">2</span></p>
<p>Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.</p>
<p>: Offspring of rat dams exposed to repaglinide at 15 times clinical exposure on a mg/m basis during days 17 to 22 of gestation and during lactation developed nonteratogenic skeletal deformities consisting of shortening, thickening, and bending of the humerus during the postnatal period. This effect was not seen at doses up to 2.5 times clinical exposure (on a mg/m basis) on days 1 to 22 of pregnancy or at higher doses given during days 1 to 16 of pregnancy. Relevant human exposure has not occurred to date and therefore the safety of PRANDIN administration throughout pregnancy or lactation cannot be established.
                                    <span class="Bold">Nonteratogenic Effects</span><span class="Sup">2</span><span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_b5881e15-8cef-4e05-82f3-309488f51716"></a><a name="section-5.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">In rat reproduction studies, measurable levels of repaglinide were detected in the breast milk of the dams and lowered blood glucose levels were observed in the pups. Cross fostering studies indicated that skeletal changes (see ) could be induced in control pups nursed by treated dams, although this occurred to a lesser degree than those pups treated . Although it is not known whether repaglinide is excreted in human milk some oral agents are known to be excreted by this route. Because the potential for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in nursing infants may exist, and because of the effects on nursing animals, a decision should be made as to whether PRANDIN should be discontinued in nursing mothers, or if mothers should discontinue nursing. If PRANDIN is discontinued and if diet alone is inadequate for controlling blood glucose, insulin therapy should be considered.
                                    <span class="Bold">Nonteratogenic Effects</span><span class="Italics">in utero</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ab91bc31-8855-4e52-a77c-a657e6116e7a"></a><a name="section-5.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">No studies have been performed in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_4bf26ba7-bfd5-4ce5-8a06-fa66e74a01b0"></a><a name="section-5.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In repaglinide clinical studies of 24 weeks or greater duration, 415 patients were over 65 years of age. In one-year, active-controlled trials, no differences were seen in effectiveness or adverse events between these subjects and those less than 65 other than the expected age-related increase in cardiovascular events observed for PRANDIN and comparator drugs. There was no increase in frequency or severity of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in older subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals to PRANDIN therapy cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_117ae122-48b7-4307-bc5b-ae126d0a296c"></a><a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: See and sections.
                            <span class="Bold"><a href="#i4i_precautions_id_1330a63a-eda5-4e62-9001-c347cb18f5fa">PRECAUTIONS</a></span><span class="Bold"><a href="#i4i_overdosage_id_895082f8-1268-4220-b9e9-54367f7c4607">OVERDOSAGE</a></span></p>
<p>PRANDIN has been administered to 2931 individuals during clinical trials. Approximately 1500 of these individuals with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> have been treated for at least 3 months, 1000 for at least 6 months, and 800 for at least 1 year. The majority of these individuals (1228) received PRANDIN in one of five 1-year, active-controlled trials. The comparator drugs in these 1-year trials were oral sulfonylurea drugs (SU) including glyburide and glipizide. Over one year, 13% of PRANDIN patients were discontinued due to adverse events, as were 14% of SU patients. The most common adverse events leading to withdrawal were <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, and related symptoms (see ). Mild or moderate <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> occurred in 16% of PRANDIN patients, 20% of glyburide patients, and 19% of glipizide patients.
                            <span class="Bold"><a href="#i4i_precautions_id_1330a63a-eda5-4e62-9001-c347cb18f5fa">PRECAUTIONS</a></span></p>
<p>The table below lists common adverse events for PRANDIN patients compared to both placebo (in trials 12 to 24 weeks duration) and to glyburide and glipizide in one year trials. The adverse event profile of PRANDIN was generally comparable to that for sulfonylurea drugs (SU).</p>
<a name="_Refid_9a630d6c-edc6-4663-9bb1-94535ceab"></a><table>
<caption><span>Commonly Reported Adverse Events (% of Patients)
                                <a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></span></caption>
<col width="24%">
<col width="23%">
<col width="17%">
<col width="17%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Events ≥ 2% for the PRANDIN group in the placebo-controlled studies and ≥ events in the placebo group</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>See trial description in ,
                                                <span class="Bold">CLINICAL PHARMACOLOGY</span><span class="Bold"><a href="#i4i_clinical_studies_id_f1b29e3f-ad55-45cb-9487-ef5b3ec06c90">Clinical Trials</a></span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" rowspan="3" valign="top"><p class="First"><span class="Bold">EVENT</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PRANDIN</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PLACEBO</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PRANDIN</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">SU</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">N = 352</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">N = 108</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">N = 1228</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Bold">N = 498</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Placebo controlled studies</span></p></td>
<td class="Botrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Active controlled studies</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Metabolic</span></p></td>
<td class="Botrule" colspan="4" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">31
                                            <a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">20</p></td>
</tr>
<tr><td class="Botrule" colspan="5" valign="top"></td></tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Respiratory</span></p></td>
<td class="Botrule" colspan="4" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">URI</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">7</p></td>
</tr>
<tr><td class="Botrule" colspan="5" valign="top"></td></tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Gastrointestinal</span></p></td>
<td class="Botrule" colspan="4" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">6</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
<tr><td class="Botrule" colspan="5" valign="top"></td></tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Musculoskeletal</span></p></td>
<td class="Botrule" colspan="4" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">7</p></td>
</tr>
<tr><td class="Botrule" colspan="5" valign="top"></td></tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="Bold">Other</span></p></td>
<td class="Botrule" colspan="4" valign="top"></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth disorder</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">&lt;1</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">&lt;1</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">&lt;1</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c43fbd02-7818-4796-9839-2d7f03683446"></a><a name="section-6.1"></a><p></p>
<h2>Cardiovascular Events</h2>
<p class="First">In one-year trials comparing PRANDIN to sulfonylurea drugs, the incidence of angina was comparable (1.8%) for both treatments, with an incidence of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> of 1.8% for PRANDIN and 1.0% for sulfonylureas. The incidence of other selected cardiovascular events (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, abnormal EKG, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>) was ≤ 1% and not different between PRANDIN and the comparator drugs.</p>
<p>The incidence of total serious cardiovascular adverse events, including <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, was higher for repaglinide (4%) than for sulfonylurea drugs (3%) in controlled comparator clinical trials. In 1-year controlled trials, PRANDIN treatment was not associated with excess mortality when compared to the rates observed with other oral hypoglycemic agent therapies.</p>
<a name="_Refid_fdf3ab51-5476-4b58-bd61-5c911da33"></a><table>
<caption><span>Summary of Serious Cardiovascular Events (% of total patients with events) in Trials Comparing PRANDIN to Sulfonylureas</span></caption>
<col width="39%">
<col width="30%">
<col width="32%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>glyburide and glipizide</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">PRANDIN</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">SU</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Total Exposed</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1228</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">498</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Serious CV Events</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">4%</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">3%</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="top"><p class="First">Cardiac Ischemic Events</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2%</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">2%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to CV Events</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.5%</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">0.4%</p></td>
</tr>
</tbody>
</table>
<p> Seven controlled clinical trials included PRANDIN combination therapy with NPH-insulin (n=431), insulin formulations alone (n=388) or other combinations (sulfonylurea plus NPH-insulin or PRANDIN plus metformin) (n=120). There were six serious adverse events of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> in patients treated with PRANDIN plus NPH-insulin from two studies, and one event in patients using insulin formulations alone from another study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_46d8fd50-95a1-4ceb-9976-d89f554ad190"></a><a name="section-6.2"></a><p></p>
<h2>Infrequent Adverse Events (&lt;1% of Patients)</h2>
<p class="First">Less common adverse clinical or laboratory events observed in clinical trials included elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
<p>Although no causal relationship with repaglinide has been established, postmarketing experience includes reports of the following rare adverse events: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, and severe hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e09b1298-d054-41fd-8c47-e2a229a7a69c"></a><a name="section-6.3"></a><p></p>
<h2>Combination Therapy with Thiazolidinediones</h2>
<p class="First">During 24-week treatment clinical trials of PRANDIN-rosiglitazone or PRANDIN-pioglitazone combination therapy (a total of 250 patients in combination therapy), <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (blood glucose &lt; 50 mg/dL) occurred in 7% of combination therapy patients in comparison to 7% for PRANDIN monotherapy, and 2% for thiazolidinedione monotherapy.</p>
<p><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span> was reported in 12 out of 250 PRANDIN-thiazolidinedione combination therapy patients and 3 out of 124 thiazolidinedione monotherapy patients, with no cases reported in these trials for PRANDIN monotherapy. When corrected for dropout rates of the treatment groups, the percentage of patients having events of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> per 24 weeks of treatment were 5% for PRANDIN-thiazolidinedione combination therapy, and 4% for thiazolidinedione monotherapy. There were reports in 2 of 250 patients (0.8%) treated with PRANDIN-thiazolidinedione therapy of episodes of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Both patients had a prior history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> and recovered after treatment with diuretic agents. No comparable cases in the monotherapy treatment groups were reported.</p>
<p>Mean change in weight from baseline was +4.9 kg for PRANDIN-thiazolidinedione therapy. There were no patients on PRANDIN-thiazolidinedione combination therapy who had elevations of liver transaminases (defined as 3 times the upper limit of normal levels).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_895082f8-1268-4220-b9e9-54367f7c4607"></a><a name="section-7"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In a clinical trial, patients received increasing doses of PRANDIN up to 80 mg a day for 14 days. There were few adverse effects other than those associated with the intended effect of lowering blood glucose. <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> did not occur when meals were given with these high doses. Hypoglycemic symptoms without <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring may continue until the physician is assured that the patient is out of danger. Patients should be closely monitored for a minimum of 24 to 48 hours, since <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may recur after apparent clinical recovery. There is no evidence that repaglinide is dialyzable using hemodialysis.</p>
<p>Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reactions</span> with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span> is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_b1ceeffc-2708-4e2b-822c-33c95c3cc684"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">There is no fixed dosage regimen for the management of type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with PRANDIN.</p>
<p>The patient's blood glucose should be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e., loss of an adequate blood glucose-lowering response after an initial period of effectiveness. <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">Glycosylated hemoglobin</span> levels are of value in monitoring the patient's longer term response to therapy.</p>
<p>Short-term administration of PRANDIN may be sufficient during periods of transient loss of control in patients usually well controlled on diet.</p>
<p>PRANDIN doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7ad0f8a-1917-4791-8a2b-21af5d2fd137"></a><a name="section-8.1"></a><p></p>
<h2>Starting Dose</h2>
<p class="First">For patients not previously treated or whose HbA is &lt; 8%, the starting dose should be 0.5 mg with each meal. For patients previously treated with blood glucose-lowering drugs and whose HbA is ≥ 8%, the initial dose is 1 or 2 mg with each meal preprandially (see previous paragraph).
                                    <span class="Sub">1c</span><span class="Sub">1c</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9bfec9c9-d73e-46b0-a2e8-46d4f50528e6"></a><a name="section-8.2"></a><p></p>
<h2>Dose Adjustment</h2>
<p class="First">Dosing adjustments should be determined by blood glucose response, usually fasting blood glucose. Postprandial glucose levels testing may be clinically helpful in patients whose pre-meal blood glucose levels are satisfactory but whose overall glycemic control (HbA ) is inadequate. The preprandial dose should be doubled up to 4 mg with each meal until satisfactory blood glucose response is achieved. At least one week should elapse to assess response after each dose adjustment.
                                    <span class="Sub">1c</span></p>
<p>The recommended dose range is 0.5 mg to 4 mg taken with meals. PRANDIN may be dosed preprandially 2, 3, or 4 times a day in response to changes in the patient’s meal pattern. The maximum recommended daily dose is 16 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7741e696-b8df-4fe2-899a-25ba194f3303"></a><a name="section-8.3"></a><p></p>
<h2>Patient Management</h2>
<p class="First">Long-term efficacy should be monitored by measurement of HbA levels approximately every 3 months. Failure to follow an appropriate dosage regimen may precipitate <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. Patients who do not adhere to their prescribed dietary and drug regimen are more prone to exhibit unsatisfactory response to therapy including <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. When <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> occurs in patients taking a combination of PRANDIN and a thiazolidinedione or PRANDIN and metformin, the dose of PRANDIN should be reduced.
                                    <span class="Sub">1c</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d95e5867-a3ba-4142-8ad2-12048654ffdb"></a><a name="section-8.4"></a><p></p>
<h2>Patients Receiving Other Oral Hypoglycemic Agents</h2>
<p class="First">When PRANDIN is used to replace therapy with other oral hypoglycemic agents, PRANDIN may be started on the day after the final dose is given. Patients should then be observed carefully for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> due to potential overlapping of drug effects. When transferred from longer half-life sulfonylurea agents (e.g., chlorpropamide) to repaglinide, close monitoring may be indicated for up to one week or longer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_31628533-12a9-4555-b799-d34599e69d26"></a><a name="section-8.5"></a><p></p>
<h2>Combination Therapy</h2>
<p class="First">If PRANDIN monotherapy does not result in adequate glycemic control, metformin or a thiazolidinedione may be added. If metformin or thiazolidinedione monotherapy does not provide adequate control, PRANDIN may be added. The starting dose and dose adjustments for PRANDIN combination therapy is the same as for PRANDIN monotherapy. The dose of each drug should be carefully adjusted to determine the minimal dose required to achieve the desired pharmacologic effect. Failure to do so could result in an increase in the incidence of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic episodes</span>. Appropriate monitoring of FPG and HbA measurements should be used to ensure that the patient is not subjected to excessive drug exposure or increased probability of secondary drug failure.
                                    <span class="Sub">1c</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d67d084d-c872-4b3a-8f88-e575d7787177"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NDC:68151-3566-8 in a PACKAGE of 1 TABLETS</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_e35e4983-ae32-4c54-8661-2aadbeabc9ac"></a><a name="section-10"></a><p></p>
<h1>Repaglinide 1 mg tabs</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e2a07020-a596-4282-bb7c-c9ebe6edcd61&amp;name=68151-3566.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRANDIN 		
					</strong><br><span class="contentTableReg">repaglinide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-3566(NDC:0169-0082)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>REPAGLINIDE</strong> (REPAGLINIDE) </td>
<td class="formItem">REPAGLINIDE</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (YELLOW) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-3566-8</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020741</td>
<td class="formItem">01/03/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-3566)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>179b453f-4a9c-4970-8f4b-ce084c748458</div>
<div>Set id: e2a07020-a596-4282-bb7c-c9ebe6edcd61</div>
<div>Version: 2</div>
<div>Effective Time: 20130411</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
